Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | ALPL | P05186 | 1/20 | 0.53 |
| ▸ | RPA1 | P27694 | 1/20 | 0.53 |
| ▸ | AXL | P30530 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | GAK | O14976 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.48 |
| ▸ | MARK1 | Q9P0L2 | 1/20 | 0.48 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70360 | 0.86 | CA12 (0.53) | CA12ALPLMEN1KMT2APOLB | |
| SCHEMBL29019950 | 0.84 | MEN1 (0.51) | RAB9AMEN1KMT2APOLBMAPT | |
| SCHEMBL69492 | 0.84 | MEN1 (0.58) | RAB9AALPLMEN1KMT2APOLB | |
| SCHEMBL1413993 | 0.83 | HCAR2 (0.55) | RAB9AALPLMEN1KMT2APOLB | |
| SCHEMBL1413913 | 0.83 | NPC1 (0.55) | RAB9ACA12ALPLMEN1KMT2A | |
| SCHEMBL1413926 | 0.83 | MEN1 (0.54) | MEN1KMT2APOLBMAPTHCAR2 | |
| SCHEMBL1413865 | 0.83 | ALPL (0.53) | ALPLMEN1KMT2APOLBMAPT | |
| SCHEMBL19996893 | 0.83 | MEN1 (0.50) | CA12ALPLMEN1KMT2APOLB | |
| Hydrochloric Acid SCHEMBL1221862 | 0.82 | MEN1 (0.57) | RAB9AALPLMEN1KMT2APOLB | |
| SCHEMBL69008 | 0.82 | MEN1 (0.50) | MEN1KMT2APOLBMAPTHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | claimed |
| US-20100160323-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-06-24 | — | — | US | claimed |
| WO-2009117676-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | WO | claimed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | claimed |
| CN-117143019-A | As beta 2 Pyrazole amide derivatives of allosteric antagonists of the adrenergic receptors | 常州大学 | 2023-12-01 | — | — | CN | disclosed |
| CN-108558760-B | Aromatic amide compounds, preparation method and application thereof | 杨国宏 | 2021-12-03 | — | — | CN | disclosed |
| US-10973810-B2 | Methods for the treatment of neurological disorders | YUMANITY THERAPEUTICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| EP-3566055-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Yumanity Therapeutics, Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| CN-108558760-A | A kind of aromatic amides and its preparation method and application | 杨国宏 | 2018-09-21 | — | — | CN | disclosed |
| US-20180193325-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-12 | — | — | US | disclosed |
| WO-2018129403-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS (US) | 2018-07-12 | — | — | WO | disclosed |
| CN-104945324-B | A kind of sulfenyl class compound and its application with antitumor activity | 沈阳药科大学 | 2017-06-13 | — | — | CN | disclosed |
| US-20100160323-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-06-24 | — | — | US | disclosed |
| EP-2108644-A1 | N-(methyl)-pyridin-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins | AC Immune S.A. (CH) | 2009-10-14 | — | — | EP | disclosed |
| WO-2009117676-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
| EP-2102165-A2 | N-(METHYL)-1H-PYRAZOL-3-AMINE, N-(METHYL)-PYRIDIN-2-AMINE AND N-(METHYL)-THIAZOL-2-AMINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS, LIKE E.G. ALZHEIMER'S | AC Immune S.A. (CH) | 2009-09-23 | — | — | EP | disclosed |
| WO-2009055437-A9 | (1,4-DIAZA-BICYCLO[3.2.2]NON-6-EN-4-YL)-HETEROCYCLYL-METHANONE LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS, USEFUL FOR THE TREATMENT OF DISEASE | MEMORY PHARM CORP (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009055437-A2 | (1,4-DIAZA-BICYCLO[3.2.2]NON-6-EN-4-YL)-HETEROCYCLYL-METHANONE LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS, USEFUL FOR THE TREATMENT OF DISEASE | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-04-30 | — | — | WO | disclosed |
| WO-2008061795-A2 | N- (METHYL) -1H- PYRAZOL- 3 -AMINE, N- (METHYL) -PYRIDIN-2-AMINE AND N- (METHYL) -THIAZ0L-2-AMINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS, LIKE E.G. ALZHEIMER'S | AC IMMUNE SA (CH) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160323-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | RAB9A 4065/4885CA12 4790/4885ALPL 3494/4885 |
| US-10973810-B2 | Methods for the treatment of neurological disorders | NLN, CLN6, OTC | RAB9A 2204/4885CA12 755/4885ALPL 3373/4885 |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | RAB9A 3858/4885CA12 4836/4885ALPL 3708/4885 |
| US-20180193325-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | RAB9A 2204/4885CA12 755/4885ALPL 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.